Tag
This study identifies distinct tumor immune microenvironment subgroups in diffuse large B-cell lymphoma based on CD163 and CD11c expression, revealing prognostic significance and potential therapeutic stratification with checkpoint inhibito
CD79B expression in diffuse large B-cell lymphoma (DLBCL) exhibits a distinct gradient aligned with cell-of-origin subtypes and germinal center B-cell differentiation stages, highlighting the biological basis for differential therapy respon
Tisagenlecleucel CAR T-cell therapy demonstrates durable responses and manageable safety in adults with relapsed or refractory diffuse large B-cell lymphoma, with 5-year data supporting its curative potential in select patients.
The POLARIX trial demonstrates superior progression-free survival with Pola-R-CHP in untreated DLBCL, highlighting the utility of patient-reported outcomes alongside clinician-reported adverse events to capture symptom burden and quality of
